Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 1/20 | 0.43 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.42 |
| ▸ | AURKA | O14965 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | PKM | P14618 | 2/20 | 0.39 |
| ▸ | ACHE | P22303 | 6/20 | 0.38 |
| ▸ | RAD52 | P43351 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | IKBKB | O14920 | 1/20 | 0.35 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7547138 | 0.93 | CCR2 (0.43) | CCR2NPY5RALDH1A1KDM4EHPGD | |
| SCHEMBL7547919 | 0.90 | AURKA (0.51) | CCR2NPY5RAURKAALDH1A1KDM4E | |
| SCHEMBL7554544 | 0.89 | ACHE (0.49) | CCR2ALDH1A1KDM4EHPGDACHE | |
| SCHEMBL7549561 | 0.89 | AURKA (0.51) | NPY5RAURKAALDH1A1KDM4EHPGD | |
| SCHEMBL7550216 | 0.86 | CCR2 (0.41) | CCR2AURKAALDH1A1ACHERAD52 | |
| SCHEMBL7549629 | 0.86 | ACHE (0.52) | CCR2ALDH1A1KDM4EHPGDACHE | |
| SCHEMBL7549560 | 0.85 | CCR2 (0.56) | CCR2NPY5RAURKAALDH1A1KDM4E | |
| SCHEMBL7160108 | 0.85 | NPY5R (0.43) | CCR2NPY5RAURKAACHERAD52 | |
| SCHEMBL7546998 | 0.85 | CCR2 (0.62) | CCR2ALDH1A1KDM4EHPGDACHE | |
| SCHEMBL7151726 | 0.84 | CCR2 (0.40) | CCR2ACHERAD52 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020099054-A1 | 2-phenyl benzimidazole derivatives as MCP-1 antagonists | WARNER-LAMBERT COMPANY (US) | 2002-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020099054-A1 | 2-phenyl benzimidazole derivatives as MCP-1 antagonists | CCR1, CCR2, CCR8 | CCR2 2/4885NPY5R 649/4885AURKA 4675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.